EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank86
3Y CAGR-3.7%
5Y CAGR+37.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-3.7%/yr
vs +70.8%/yr prior
5Y CAGR
+37.7%/yr
Recent deceleration
Acceleration
-74.4pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
5x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 66.29% |
| 2024 | 105.57% |
| 2023 | 30.26% |
| 2022 | 74.18% |
| 2021 | 63.57% |
| 2020 | 13.38% |
| 2019 | -5.01% |
| 2018 | 8.72% |
| 2017 | 3.47% |
| 2016 | 18.97% |